🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

With new #startup, immunotherapy pioneer Lieping Chen tries to turn ‘cold’ tumors ‘hot’ biopharmadive.com/news/normunity… $NXTC $AZN $BMY $MRK

Introducing Normunity, opening new frontiers in immuno-oncology. We reveal hidden mechanisms to free the immune system to work normally against cancer. These are novel targets for our new class of #ImmuneNormalizers to cure cancer. #ImmunoOncology normunity.com

Normunity announces $65 million Series A to expand the frontier of precision immuno-oncology with immune normalizer therapies. Our medicines target unprecedented mechanisms that free the body’s normal immunity against cancer. #NormunityAgainstCancer normunity.com/normunity-anno…

Normunity’s pipeline of novel cancer immunotherapies is drawn from the ongoing & interactive academic-biotech research leveraging proprietary discovery platforms from the lab of Dr. Lieping Chen at Yale School of Medicine. #NormunityAgainstCancer normunity.com

Normunity, which combines the words normal and immunity, is launching out of stealth with a $65 million Series A. The 15-month-old West Haven and Boston-based biotech wants to address T cell exclusion, or when T cells can’t get into tumors. endpts.com/pd-l1-pioneer-…

We’re thrilled to unveil Normunity to the biotech world. @bostonglobe Ryan Cross the Science Boss explores our revolutionary approach to novel cancer immunotherapies that free the normal immune system to fight cancer. #NormunityAgainstCancer bostonglobe.com/2022/10/25/bus…

Normunity has launched with 1) a powerful premise to reach novel I-O targets to free normal immunity, 2) a unique R&D model working with the Lieping Chen lab and 3) strong momentum to advance life-changing medicines for patients. #NormunityAgainstCancer normunity.com

Congratulations to the Normunity team for today’s exciting launch. Looking forward to great things and #ImmuneNormalizers to come. #NormunityAgainstCancer normunity.com

Normunity was well represented at SITC Friday night by our very own CEO Rachel Humphrey who was on stage with the Checkpoints Band! #SITC2022 #Checkpoints

Christina Cho, PhD, Rachel Humphrey, CEO, and Melinda Merchant, SVP Clinical Development enjoying the sessions at SITC #SITC2022

Today we announced a multi-program collaboration that leverages Alloy’s high-velocity antibody discovery offering to accelerate Normunity’s novel precision #ImmunoOncology pipeline. #ImmuneNormalizers businesswire.com/news/home/2022…

Today is #AdministrativeProfessionalsDay, and the Normunity team is sending a special thank you to Suzanne, who keeps us all on track as a stellar contributor to our success and progress in our fight against cancer.